Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 analogue with 97 % amino acid homology with native glucagon-like peptide-1 and greatly protracted action. It is widely used for the treatment of type 2 diabetes mellitus, and administered by subcutaneous injection once daily. The pharmacokinetic properties of liraglutide enable 24-h exposure coverage, a requirement for 24-h glycaemic control with once-daily dosing. The mechanism of protraction relates to slowed release from the injection site, and a reduced elimination rate owing to metabolic stabilisation and reduced renal filtration. Drug exposure is largely independent of injection site, as well as age, race and ethnicity. Increasing body weight and male sex are associated with reduced concentrations, but there is substantial overlap between subgroups; therefore, dose escalation should be based on individual treatment outcome. Exposure is reduced with mild, moderate or severe renal or hepatic impairment. There are no clinically relevant changes in overall concentrations of various drugs (e.g. paracetamol, atorvastatin, griseofulvin, digoxin, lisinopril and oral combination contraceptives) when co-administered with liraglutide. Pharmacodynamic studies show multiple beneficial actions with liraglutide, including improved fasting and postprandial glycaemic control (mediated by increased insulin and reduced glucagon levels and minor delays in gastric emptying), reduced appetite and energy intake, and effects on postprandial lipid profiles. The counter-regulatory hormone response to hypoglycaemia is largely unaltered. The effects of liraglutide on insulin and glucagon secretion are glucose dependent, and hence the risk of hypoglycaemia is low. The pharmacokinetic and pharmacodynamic properties of liraglutide make it an important treatment option for many patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Primary structure of liraglutide. Compared with native GLP-1 (7–37), liraglutide has lysine replaced with arginine in position 34, and the lysine at position 26 is acylated on its ε-amino group with the γ-carboxyl group of N-palmitoyl-l-glutamic acid. GLP-1 glucagon-like peptide-1. Republished with permission of © Dove Medical Press Ltd. from Deacon. Vasc Health Risk Manag. 2009;5:199–211 [21]; permission conveyed through Copyright Clearance Center, Inc](https://figures.cochat.ai/paper-figures/c2eb76f98855443e8c48117058c2da8f/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-1.jpg)
![Fig. 2 Mean concentration profiles of liraglutide following steady-state doses of 0.6 mg (n = 9), 1.2 mg (n = 9) and 1.8 mg (n = 8) in healthy male Chinese subjects. With permission of © John Wiley & Sons, Inc. from Jiang et al. J Clin Pharmacol. 2011;51:1620–7 [42]](https://figures.cochat.ai/paper-figures/30d2b29ba4374c538da71ae99f6176f8/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-2.jpg)
![Fig. 3 Model-derived steady-state concentration profile of liraglutide (20 μg/kg) dosed once daily. With permission of © John Wiley & Sons, Inc.; adapted from Watson et al. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol. 2010;50:886–94 [46]](https://figures.cochat.ai/paper-figures/45e09538af3940d0b7122b25a9e38153/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-3.jpg)
![Fig. 4 Dose-proportionality plot of liraglutide exposure at steady state. Open circles represent individual study subjects. Squares represent mean values at each dose in healthy male Chinese subjects. The line represents the regression line from a linear model with logarithmic transformed AUC and dose under the assumption of dose proportionality (r 2 = 0.96). AUC area under the concentration–time curve in a dosing interval (24 h). Data from Jiang et al. The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects. J Clin Pharmacol 2011;51:1620–7 [42] © John Wiley and Sons, analysis results from data on file](https://figures.cochat.ai/paper-figures/ddf261cb8e78429c8a1df714b4a57f05/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-4.jpg)
![Fig. 5 Forest plot of covariate effects on liraglutide dose-normalised exposure (AUC) relative to a reference subject (Chinese female individual aged <65 years and with a body weight of 67 kg). Data are mean (90 % CI). Vertical dotted lines indicate bioequivalence limits of 0.8–1.25. The column to the right provides numerical values of geometric mean relative exposures with 90 % CIs obtained by likelihood profiling. AUC area under the concentration–time curve, CI confidence interval, y years. Reprinted from Ingwersen et al. Diabetes Res Clin Pract. 2015;108:113–9 [35], with permission from © Elsevier Ireland Ltd](https://figures.cochat.ai/paper-figures/9ae31b3760294c56846f9721efb6b2c0/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-5.jpg)
![Fig. 6 Liraglutide exposure (AUC and C max) following liraglutide 0.75 mg in subjects with renal or hepatic impairment relative to healthy controls. Data are mean exposures (with 90 % CI) for each group (n = 5–7 per group) relative to healthy subjects. Broken vertical lines illustrate the no-effect boundaries (0.70–1.43) used in the assessment. AUC area under the concentration–time curve, CI confidence interval, C max maximum concentration. Renal impairment data from Jacobsen et al. Br J Clin Pharmacol. 2009;68:898–905 [41]. Hepatic impairment data from Flint et al. Br J Clin Pharmacol. 2010;70:807–14 [38]](https://figures.cochat.ai/paper-figures/a0810b5790e44bf798f1584788234420/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-6.jpg)
![Fig. 7 Effects of liraglutide 1.8 mg on the exposure of selected co-administered drugs. Data are mean relative exposures (with 90 % CI) when co-administered with liraglutide vs. co-administration with placebo. The trials consisted of healthy subjects (atorvastatin n = 42, griseofulvin n = 27, lisinopril n = 38, digoxin n = 26, ethinylestradiol/levonorgestrel n = 21) and subjects with type 2 diabetes (acetaminophen n = 18 and insulin detemir n = 32). Broken vertical lines illustrate the no-effect boundaries (0.80–1.25) used in the assessment. Ethinylestradiol and levonorgestrel were administered as a combination product. AUC area under the concentration–time curve, C max maximum concentration. Data from Malm-Erjefält et al. Mol Pharm. 2015; doi: 10.1021/acs.molpharmaceut.5b00278 [44]; Jacobsen et al. J Clin Pharmacol. 2011;51:1696–703 [53]; Kapitza et al. Adv Ther. 2011;28:650–60 [54]; Morrow et al. Diabetes Obes Metab. 2011;13:75–80 [56]](https://figures.cochat.ai/paper-figures/37caac17c046495f89192b8208f70a03/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-7.jpg)
![Fig. 8 Mean postprandial glucose profiles during a standardised meal test performed in 18 subjects with type 2 diabetes dosed with liraglutide or placebo. During each 3-week treatment period, the liraglutide/placebo dose was escalated weekly in 0.6-mg increments from 0.6 to 1.2 mg and 1.8 mg. Postprandial glucose measures were performed at steady-state liraglutide 0.6-mg (red squares), 1.2-mg (blue triangles), and 1.8-mg (green circles) doses, and for placebo (matched grey lines). © With kind permission from Springer Science + Business Media: Advances in Therapy, The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. 2011;28:213–26, Flint et al., Fig. 1 [61]](https://figures.cochat.ai/paper-figures/5594525b0f3f4263b57258969e95bbd6/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-8.jpg)
![Fig. 9 Mean insulin profiles following glucose bolus injection (inserted), during a hyperglycaemic clamp and following an arginine stimulation test in 13 subjects with type 2 diabetes treated for 9 days with liraglutide 6 µg/kg (~0.55 mg) or placebo. Glucose bolus (first phase): 0–17 min; hyperglycaemic clamp (second phase): 90–120 min; arginine stimulation test (maximum insulin secretion): 120–150 min. © American Diabetes Association. Diabetes, American Diabetes Association, 2004. Copyright and all rights reserved. Material from this publication has been adapted with the permission of the American Diabetes Association from Degn et al. Diabetes. 2004;53:1187–94 [66]](https://figures.cochat.ai/paper-figures/a712653b361e4c7f8711556001fe9bdb/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-9.jpg)
![Fig. 10 Glucose-dependent stimulation of insulin secretion in subjects with type 2 diabetes treated with liraglutide. Relationship between insulin secretion rate (ISR) and plasma glucose levels during graded glucose infusion in subjects with type 2 diabetes (n = 10) receiving liraglutide 7.5 µg/kg (~0.66 mg; blue squares) or placebo (grey circles). Values from healthy controls (n = 10) who did not receive liraglutide (black triangles) are also shown. ISR was derived by deconvolution of C-peptide concentrations. Data are mean ± standard error; n = 10 for each group. © American Diabetes Association. Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association. From Chang et al. Diabetes. 2003;52:1786–91 [59]](https://figures.cochat.ai/paper-figures/812592d9e79648288b7bf0978e489da9/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-10.jpg)
![Fig. 11 Exposure–response relationship of liraglutide effects on HbA1c in subjects with type 2 diabetes. Figure shows percentage change from baseline in HbA1c following 14 weeks of treatment in a phase II dose-finding study (grey circles) and following 12 weeks of treatment in a phase III study (blue squares). The exposure–response relationships were evaluated by dividing liraglutide concentration values from each trial into quartiles. Exposures are trough concentrations for the phase II trial and model-derived mean concentrations for the phase III trial. HbA 1c glycated haemoglobin, SE standard error. With permission of © John Wiley & Sons, Inc.; adapted from Ingwersen et al. Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment. J Clin Pharmacol. 2012;52:1815–23 [33]](https://figures.cochat.ai/paper-figures/b7e333da49824b5a99bb3c107e08b4c5/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-11.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the treatment of T2DM, liraglutide helps lower blood sugar levels by increasing insulin production and reducing glucose production by the liver.81”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [81]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“In any case, it has been suggested that the effect of liraglutide on gastric emptying decreases over time, owing to tolerance development as a result of continuous activation of the GLP-1 receptor [79].”
BackgroundNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“However, although intravenous infusion of native GLP-1 can normalise plasma glucose levels in patients with type 2 diabetes [22, 23], it is not a practical option for exogenous therapy.”
BackgroundGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 8×
“Based on data from a phase III study in the USA, as well as a dose-finding phase II study, the mean change from baseline in HbA1c at 12–14 weeks was plotted for various doses of liraglutide (up to 1.8 mg and including placebo) given as monotherapy [33].”
BackgroundMethodInfluentialGhoos, Y. F., Maes, B. D., Geypens, B. J., Mys, G., Hiele, M. I., Rutgeerts, P. J., & Vantrappen, G. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90640-x · Cited by 946
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700 · cited 3×
“The following main mechanisms underlie the protraction of liraglutide: (1) slowed absorption following subcutaneous injection [31]; and (2) reduced elimination rate owing to slowed metabolism and renal filtration [30, 32].”
BackgroundBuse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 2×
“A validated two-site enzyme-linked immunosorbent assay has been developed, using two monoclonal antibodies directed against different liraglutide epitopes [36].”
MethodResultDungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Postprandial lipoprotein metabolism and atherosclerosis.
Karpe, F. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00548.x · Cited by 360
Pratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312 · cited 3×
“6 % with glimepiride), as were reductions in fat mass [64].”
BackgroundMethodInfluentialZinman, B., Gerich, J. E., Buse, J. B., Lewin, A., Schwartz, S. E., Raskin, P., Hale, P. M., Zdravkovic, M. D., & Blonde, L. (2010) · Diabetes Care · Cited by 290
Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279 · cited 2×
“This is in line with results from several pharmacokinetic evaluations in healthy and subjects with type 2 diabetes, which also indicated dose proportionality [35, 36, 40, 45].”
BackgroundResultMeier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276 · cited 1×
“The beneficial effect of liraglutide on the postprandial lipid response aligns with results from trials of native GLP-1 [70].”
Rachman, J., Barrow, B. A., Levy, J. C., & Turner, R. C. (1997) · Diabetologia · doi:10.1007/s001250050664 · Cited by 269 · cited 1×
“However, although intravenous infusion of native GLP-1 can normalise plasma glucose levels in patients with type 2 diabetes [22, 23], it is not a practical option for exogenous therapy.”
BackgroundJuhl, C. B., Hollingdal, M., Sturis, J., Jakobsen, G., Agersø, H., Veldhuis, J., Pørksen, N., & Schmitz, O. (2002) · Diabetes · doi:10.2337/diabetes.51.2.424 · Cited by 264 · cited 1×
“9 mg; doses were converted from lg/kg to mg dose using individual body weights), which showed substantially improved fasting and postprandial glycaemia in subjects with type 2 diabetes [58].”
MethodSoluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs
Markussen, J., Havelund, S., Kurtzhals, P., Andersen, A. S., Halstr�m, J., Hasselager, E., Larsen, U. D., Ribel, U., Sch�ffer, L., Vad, K., et al. (1996) · Diabetologia · doi:10.1007/bf00418343 · Cited by 233
Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide
Jacobsen, L. V., Hindsberger, C., Robson, R., & Zdravkovic, M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03536.x · Cited by 215 · cited 2×
“However, there was no clear trend for a relationship between creatinine clearance and exposure of liraglutide [41].”
BackgroundSelf-citationVilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
How Useful Is Paracetamol Absorption as a Marker of Gastric Emptying? A Systematic Literature Study
Willems, M., Quartero, A. O., & Numans, M. E. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1011935603893 · Cited by 211
Chang, A. M., Jakobsen, G., Sturis, J., Smith, M. J., Bloem, C. J., An, B., Galecki, A., & Halter, J. B. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1786 · Cited by 207 · cited 1×
“66 mg]) stimulated insulin secretion in a glucose-dependent manner [59].”
BackgroundMalm-Erjefält, M., Bjørnsdottir, I., Vanggaard, J., Helleberg, H., Larsen, U., Oosterhuis, B., van Lier, J. J., Zdravkovic, M., & Olsen, A. K. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034066 · Cited by 201 · cited 4×
“The following main mechanisms underlie the protraction of liraglutide: (1) slowed absorption following subcutaneous injection [31]; and (2) reduced elimination rate owing to slowed metabolism and renal filtration [30, 32].”
BackgroundSelf-citationIepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1176 · Cited by 193 · cited 1×
“In contrast, the control group which obtained a similar diet-induced weight reduction as the treatment group exhibited a reduced bone mineral content [82].”
ResultHorowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · cited 5×
“Similar results were achieved in a crossover study of gastric emptying after 4 weeks of treatment [62].”
BackgroundResultSelf-citationPlamboeck, A., Holst, J. J., Carr, R. D., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1847-7 · Cited by 173
DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1928 · Cited by 159 · cited 1×
“GLP-1 analogues are often used in combination with insulin products, and liraglutide in combination with insulin detemir and insulin degludec has been shown to provide good glycaemic control, sustained weight loss and low rates of hypoglycaemia [16, 55].”
BackgroundMathieu, C., Rodbard, H. W., Cariou, B., Handelsman, Y., Philis‐Tsimikas, A., Ocampo Francisco, A. M., Rana, A., Zinman, B., & on behalf of the BEGIN: VICTOZA ADD‐ON (NN1250‐3948) study group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12262 · Cited by 158 · cited 2×
“5 %, whether given as monotherapy or as combination therapy with metformin, glimepiride, rosiglitazone or insulin [15, 16].”
BackgroundLiraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight
Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Bjerre Knudsen, L. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 155 · cited 1×
“rat model showed that inhibition of gastric emptying diminished markedly over the course of 14 days of twicedaily liraglutide administration [80].”
BackgroundBuse, J. B., Garber, A., Rosenstock, J., Schmidt, W. E., Brett, J. H., Videbæk, N., Holst, J., & Nauck, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2822 · Cited by 154 · cited 1×
“because of the high level of amino acid homology to native GLP-1, liraglutide has low immunogenicity [28].”
BackgroundHermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143 · cited 4×
“8 mg were all shown to increase insulin concentration relative to placebo in patients with type 2 diabetes, following a standardised meal [39, 61].”
BackgroundResultSelf-citationEffects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138 · cited 1×
“GLP-1 agonists have been reported to slow gastric emptying as a result of reduced gastrointestinal motility [71].”
BackgroundCunningham, K. M., & Read, N. W. (1989) · British Journal of Nutrition · doi:10.1079/bjn19890116 · Cited by 106 · cited 1×
“However, the meal provided prior to assessment was high in fat, which is known to delay gastric emptying [78] and hence could have masked any additional effect of liraglutide.”
BackgroundKlein, D. J., Battelino, T., Chatterjee, D. J., Jacobsen, L. V., Hale, P. M., Arslanian, S., & on behalf of the NN2211-1800 Study Group (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0366 · Cited by 101 · cited 1×
“Liraglutide Cmax increased linearly with dose [48].”
Self-citationNiswender, K., Pi‐Sunyer, X., Buse, J., Jensen, K. H., Toft, A. D., Russell‐Jones, D., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01673.x · Cited by 100 · cited 2×
“, among subjects treated with liraglutide who experienced gastrointestinal adverse events at[7,[14 and[30 days after treatment, a slightly greater weight reduction was observed in subjects with a longer duration of the adverse events [81].”
BackgroundIdorn, T., Knop, F. K., Jørgensen, M. B., Jensen, T., Resuli, M., Hansen, P. M., Christensen, K. B., Holst, J. J., Hornum, M., & Feldt-Rasmussen, B. (2016) · Diabetes Care · doi:10.2337/dc15-1025 · Cited by 96 · cited 1×
“In contrast, however, in a study of subjects with type 2 diabetes and end-stage renal disease undergoing dialysis treatment, plasma liraglutide concentrations were higher than in subjects with type 2 diabetes and normal renal function [51].”
ResultYang, W., Chen, L., Ji, Q., Liu, X., Ma, J., Tandon, N., Bhattacharyya, A., Kumar, A., Kim, K. ‐., Yoon, K. ‐., et al. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01323.x · Cited by 91
Flint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91 · cited 5×
“1 [61] Clinical PK/PD of Liraglutide in Type 2 DM 665”
BackgroundSelf-citationPlum, A., Jensen, L. B., & Kristensen, J. B. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23648 · Cited by 89 · cited 1×
“non-covalently bound to the dominant plasma protein, human serum albumin ([99 % in vitro) [29], which is most likely via a fatty acid-binding site [30].”
BackgroundDamholt, B., Golor, G., Wierich, W., Pedersen, P., Ekblom, M., & Zdravkovic, M. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006288215 · Cited by 82 · cited 2×
“Exposure (AUC and Cmax) was equivalent between male and female healthy subjects when correcting for body weight following a single dose of 1 mg of liraglutide [37].”
BackgroundBlase, E., Taylor, K., Gao, H., Wintle, M., & Fineman, M. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004274432 · Cited by 82
Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide
Flint, A., Nazzal, K., Jagielski, P., Hindsberger, C., & Zdravkovic, M. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03762.x · Cited by 80 · cited 1×
“2010;70:807–14 [38] Clinical PK/PD of Liraglutide in Type 2 DM 663”
BackgroundSelf-citationPotential of liraglutide in the treatment of patients with type 2 diabetes
Deacon, C. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4039 · Cited by 74 · cited 4×
“GLP-1 enhances meal-induced insulin secretion, the so-called ‘incretin effect’, and has several other actions that are desirable for an anti-diabetic agent [21].”
BackgroundInfluentialRenal catabolism of human glucagon-like peptides 1 and 2
Ruiz-Grande, C., Pintado, J., Alarcón, C., Castilla, C., Valverde, I., & López-Novoa, J. M. (1990) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y90-239 · Cited by 72
Pharmacokinetic Drug Interactions with Gastrointestinal Motility Modifying Agents
Greiff, J. M. C., & Rowbotham, D. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199427060-00004 · Cited by 72
Renal Catabolism of Truncated Glucagon-Like Peptide 1
Ruiz-Grande, C., Alarcón, C., Alcántara, A., Castilla, C., López Novoa, J., Villanueva-Peñacarrillo, M., & Valverde, I. (1993) · Hormone and Metabolic Research · doi:10.1055/s-2007-1002190 · Cited by 68
Barnett, A. H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01523.x · Cited by 54 · cited 2×
“The glucose-dependent action of liraglutide on insulin secretion is in line with the low risk of hypoglycaemia observed in clinical trials with liraglutide [15].”
BackgroundResultChatterjee, D. J., Khutoryansky, N., Zdravkovic, M., Sprenger, C. R., & Litwin, J. S. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009339189 · Cited by 54 · cited 1×
“Hence, liraglutide has no clinically relevant effects on the corrected QT interval [83].”
BackgroundWatson, E., Jonker, D. M., Jacobsen, L. V., & Ingwersen, S. H. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009354996 · Cited by 53 · cited 1×
“subjects with type 2 diabetes regardless of the dose levels used [46].”
BackgroundSelf-citationLiraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0321-6 · Cited by 47
Gastric emptying: a comparison of three methods
Glerup, H., Bluhme, H., Villadsen, G. E., Rasmussen, K., Ejskjaer, N., & Dahlerup, J. F. (2007) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520701370922 · Cited by 45
Flint, A., Kapitza, C., & Zdravkovic, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12108 · Cited by 42 · cited 2×
“To seek explanations for the body weight loss observed with liraglutide treatment, the effects of liraglutide on appetite sensations, energy intake and energy expenditure have been assessed in subjects with type 2 diabetes [62, 65].”
BackgroundSelf-citationJacobsen, L. V., Vouis, J., Hindsberger, C., & Zdravkovic, M. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010389471 · Cited by 41 · cited 1×
“These effects were not considered to be clinically relevant [44, 53, 54] and dose adjustments for co-administered drugs are not required [18, 19].”
BackgroundSelf-citationMorrow, L., Hompesch, M., Guthrie, H., Chang, D., & Chatterjee, D. J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01322.x · Cited by 39 · cited 1×
“lowering effect without affecting the pharmacokinetic profile of either agent (as evaluated by AUC, Cmax and tmax) [56].”
Irie, S., Matsumura, Y., Zdravkovic, M., Jacobsen, L. V., & Kageyama, S. (2008) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp46273 · Cited by 38 · cited 3×
“The pharmacokinetic profile of liraglutide in healthy Japanese [40] and Chinese [42] subjects was also found to be consistent with other race groups.”
ResultSelf-citationLiraglutide: from clinical trials to clinical practice
Gough, S. C. L. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01576.x · Cited by 38 · cited 1×
“However, the frequency of reported nausea has been shown to be dose dependent and transient in nature, as discussed by Gough [84].”
BackgroundKapitza, C., Zdravkovic, M., Hindsberger, C., & Flint, A. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0044-y · Cited by 36 · cited 1×
“These effects were not considered to be clinically relevant [44, 53, 54] and dose adjustments for co-administered drugs are not required [18, 19].”
BackgroundSelf-citationMalm-Erjefält, M., Ekblom, M., Vouis, J., Zdravkovic, M., & Lennernäs, H. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00278 · Cited by 36 · cited 1×
“These effects were not considered to be clinically relevant [44, 53, 54] and dose adjustments for co-administered drugs are not required [18, 19].”
BackgroundDosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment
Ingwersen, S. H., Khurana, M., Madabushi, R., Watson, E., Jonker, D. M., Thi, T. D. L., Jacobsen, L. V., & Tornøe, C. W. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011430504 · Cited by 35 · cited 10×
“8 mg and including placebo) given as monotherapy [33].”
BackgroundMethodSelf-citationHermans, M. P., Brotons, C., Elisaf, M., Michel, G., Muls, E., & Nobels, F. R. E. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312449414 · Cited by 35 · cited 1×
“Control of hyperglycaemia is suboptimal in many patients, with only around 50 % achieving glycaemic targets, even in resourcerich settings [4].”
BackgroundPetri, K. C. C., Jacobsen, L. V., & Klein, D. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0229-z · Cited by 32 · cited 1×
“With regard to paediatric patients with type 2 diabetes, liraglutide exposure in subjects aged 10–17 years has been shown to be similar to that observed in adults [47].”
BackgroundSelf-citationOsonoi, T., Saito, M., Tamasawa, A., Ishida, H., Tsujino, D., Nishimura, R., & Utsunomiya, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113468 · Cited by 31
Carstensen, M., Thomsen, C., Gotzsche, O., Holst, J. J., Schrezenmeir, J., & Hermansen, K. (2004) · The Review of Diabetic Studies · doi:10.1900/rds.2004.1.175 · Cited by 30
Meece, J. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.pt2.33s · Cited by 30
Kapitza, C., Bode, B. W., Ingwersen, S. H., Jacobsen, L. V., & Poulsen, P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.549 · Cited by 28 · cited 1×
“Using a fixed-dose combination of liraglutide and insulin degludec (IDegLira) with preserved pharmacokinetic properties of the two active components, treatment benefits were seen across the entire dose and exposure range compared with each component dosed alone [57].”
BackgroundSelf-citationJiang, J., Zhang, J., Jacobsen, L. V., & Hu, P. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010389468 · Cited by 28 · cited 3×
“J Clin Pharmacol 2011;51:1620–7 [42] John Wiley and Sons, analysis results from data on file Clinical PK/PD of Liraglutide in Type 2 DM 661”
BackgroundResultSelf-citationKapitza, C., Zdravkovic, M., Zijlstra, E., Segel, S., Heise, T., & Flint, A. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010374474 · Cited by 21 · cited 1×
“The effect of the site of injection (abdomen, upper arm or thigh) on the pharmacokinetic profile of liraglutide has been investigated in healthy subjects [43].”
BackgroundSelf-citationIngwersen, S. H., Petri, K. C. C., Tandon, N., Yoon, K.-H., Chen, L., Vora, J. P., & Yang, W. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.01.001 · Cited by 15 · cited 12×
“In two population pharmacokinetic analyses of subjects with type 2 diabetes, mean liraglutide exposure was greater for female than male individuals after correction for differences in body weight [33, 35].”
BackgroundMethodResultSelf-citationNgo, P., Davies, M. J., Atkin, S. L., Bain, S. C., Rossing, P. R., Scott, D. S., Шамхалова, М. Ш., Bosch‐Traberg, H., Syrén, A., & Umpierrez, G. E. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.07.020 · Cited by 6
Research works printed but not linked: 1
- International Diabetes Federation. Diabetes atlas: sixth edition. 2014 update. http://www.idf.org/diabetesatlas. Accessed 24 Sep 2015.
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“The acylation also promotes multimeric formation, which decelerates diffusion from the site of injection [893].”
BackgroundGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“81,107,109 Tanzeum was discontinued by GlaxoSmithKline (GSK) in 2017, primarily due to economic factors.”
BackgroundEmerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
“liraglutide’s pharmacokinetic properties allow for 24 h glycemic management with a single dose, owing to metabolic stabilization and reduced renal filtration that slow down release from the injection site and eliminate the medication more slowly [84].”
BackgroundRecent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
Metadata
- Authors
- Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Ingwersen, Steen H.
- ORCID
- Flint, Anne
- Venue
- Clinical Pharmacokinetics
- Published
- 2015-11-23
- Volume
- 55
- Issue
- 6
- Pages
- 657-672
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC4875959
- OpenAlex
- W2174832318
- Cited by
- 217
- References
- 78
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 43 · 2023: 34 · 2022: 20 · 2021: 14 · 2020: 18 · 2019: 20 · 2018: 11 · 2017: 4 · 2016: 7 · 2015: 1
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, type 2 diabetes, glucagon-like peptide-1 analogues, pharmacokinetics, pharmacodynamics, glycemic control, insulin secretion, glucagon secretion, gastric emptying, hypoglycemia, renal dysfunction, liver dysfunction, drug interactions, dose escalation, subcutaneous injection
- MeSH terms
- Liraglutide, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Interactions, Glucagon, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Lipids, Sex Factors, Liver Failure, Area Under Curve, Renal Insufficiency, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.